DeepMed Research

NEUROCRINE BIOSCIENCES, INC.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: Public

Established: 1992-01-01

Employees: 1.4K

Market Cap: $15.4B

Website: http://www.neurocrine.com

Clinical Trials

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Phase 2

Active, not recruiting

Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome

Interventions: Drug: Placebo
Drug: NBI-921352

First Posted Date: 2021-05-05

Last Posted Date: 2025-02-28

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 52

Registration Number: NCT04873869

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 6 locations

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Phase 3

Active, not recruiting

Conditions: Congenital Adrenal Hyperplasia

Interventions: Drug: Crinecerfont
Drug: Placebo

First Posted Date: 2021-03-19

Last Posted Date: 2025-02-05

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 103

Registration Number: NCT04806451

Locations: 🇬🇧
Neurocrine Clinical Site, London, United Kingdom
🇺🇸
Neurocrine Clinical site, Saint Louis, Missouri, United States

Opicapone Treatment Initiation Open-Label Study

Completed

Conditions: Parkinson Disease

Interventions: Drug: Opicapone

First Posted Date: 2021-03-09

Last Posted Date: 2022-11-28

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 239

Registration Number: NCT04787965

Locations: 🇺🇸
Neurocrine clinical site, Crab Orchard, West Virginia, United States

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase 2

Completed

Conditions: Continuous Spike and Wave During Sleep
Epileptic Encephalopathy

Interventions: Drug: Placebo
Drug: NBI-827104

First Posted Date: 2020-11-12

Last Posted Date: 2023-08-04

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 24

Registration Number: NCT04625101

Locations: 🇬🇧
Neurocrine Clinical Site, London, United Kingdom

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

Phase 3

Active, not recruiting

Conditions: Congenital Adrenal Hyperplasia

Interventions: Drug: Crinecerfont
Drug: Placebo

First Posted Date: 2020-07-29

Last Posted Date: 2025-02-05

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 182

Registration Number: NCT04490915

Locations: 🇬🇧
Neurocrine Clinical Site, Salford, United Kingdom

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Phase 3

Active, not recruiting

Conditions: Chorea, Huntington

Interventions: Drug: Valbenazine

First Posted Date: 2020-05-22

Last Posted Date: 2024-12-24

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 154

Registration Number: NCT04400331

Locations: 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-831 Oral Tablet
Drug: [14C]TAK-831 IV Infusion
Drug: [14C]TAK-831 Oral Suspension

First Posted Date: 2020-01-21

Last Posted Date: 2021-06-30

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 6

Registration Number: NCT04234672

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Phase 3

Completed

Conditions: Chorea, Huntington

Interventions: Drug: Valbenazine
Drug: Placebo

First Posted Date: 2019-09-25

Last Posted Date: 2023-10-11

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 128

Registration Number: NCT04102579

Locations: 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

Phase 2

Completed

Conditions: CAH - Congenital Adrenal Hyperplasia

Interventions: Drug: Crinecerfont

First Posted Date: 2019-08-05

Last Posted Date: 2024-07-18

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 8

Registration Number: NCT04045145

Locations: 🇺🇸
Neurocrine Clinical Site, Seattle, Washington, United States

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Phase 4

Completed

Conditions: Tardive Dyskinesia (TD)

Interventions: Drug: Placebo oral capsule
Drug: Valbenazine

First Posted Date: 2019-03-27

Last Posted Date: 2021-04-20

Lead Sponsor: Neurocrine Biosciences

Target Recruit Count: 135

Registration Number: NCT03891862

Locations: 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy